We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
16/7/20
Next steps and summary
Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial
PhaseII/III trial in ARDS patients commencing shortly - COVID-19
Reduce risk and increase probability of success by expanding breadth of clinical programmes:
Grant-funded, investigator-led clinical trials (no/smallcost to Evgen)
In indications with a strong mechanistic rationale (four collaborations announced todate in non-cancer indications)
Seek commercial partnerships based on PhaseII results
Continue to explore other opportunities to monetise our IP assets
CEO recruitment process well-advanced
http://evgen.com/wp-content/uploads/2020/07/EVG-AGM-presentation-2020-16Jul20.pdf
News of the appointment of the new CEO for starters which could be transformational depending on who it is, background/experience and whether it could be connected to a strategic JV investment, although whoever they appoint, the new CEO should be the catalyst for flow of news thereafter on the rest of the pipeline and potential JV's, including the Covid-19 patient trials which should be up and running next week according to Prof Chalmers research website. Gl ;-)
On what fronts are you expecting news MoneyMunch (or anyone else).
Considering a cut and run or average down, I need to do something one way or another here, and I must admit it is a share I have not been actively managing as I should.
Some decent sized buy orders on the book..
Tree shake prior to imminent news with any luck. Gla :-)
https://seekingalpha.com/article/4375552-reata-pharmaceuticals-can-rally
The company’s most advanced candidates, bardoxolone methyl (Bard) and omaveloxolone (Omav), target transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
There's more to EVG than SFX-01 'a potential as a treatment for Covid-19, but like it or lump it , it looks as if the UK are on the brink of a second wave, and so hopefully SFX-01 will prove to be an effective therapy.
Ps SNG's market cap was £380m, the sp now on the slide with a current market cap of £275m, and will slide significantly further until they confirm their phase 3 trials have started, which could be months away...meanwhile EVG's SFX-01 Covid-19 phase 2/3 patient trials , with a ridiculous low £16m market cap are just about to start, and news also expected imminently on the new CEO and no doubt an update on the rest of the pipeline...Exciting times...Gla :-)
SNG Covid-19 trials were small compared with SFX-01 planned trials. Gla ;-)
James D Chalmers
@ProfJDChalmers
A link to the presentation of the interferon beta data from todays conference call. Encouraging data but we should be cautious in interpreting small trials, particularly when full data not available yet #COVID19
https://synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-data-readout-final-version.pdf
SFX-01's Covid-19 patient trials, probably delayed because of the low number of hospitalised patients over the last few months, which now look like to be on the increase.
New hospital admissions for England: the increase is real and serious. Doubling time: 8 days.
hTtps://twitter.com/richardhorton1/status/1306937064445874176
Since Monday morning, we have recruited more people into RECOVERY than we did in the whole of August.
3:55 PM · Sep 18, 2020·Twitter Web App
https://twitter.com/MartinLandray/status/1306970127619903490
https://www.recoverytrial.net/
Start date 1/10/20....Gla ;-)
...........................
Not started
A randomized controlled trial of SFX-01 to improve clinical outcomes in COVID-19 patients (STAR-COVID)
Chalmers, J. & Dinkova-Kostova, A.
LifeArc
1/10/20 ? 30/09/21
https://discovery.dundee.ac.uk/en/persons/james-chalmers/projects/?status=NOT_STARTED